Human C peptide, a short 31-amino acid polypeptide, is synthesized as a byproduct during the production of insulin in the pancreatic β-cells. The release ratio of insulin to C-peptide is almost 1:1 making it an important clinical marker for evaluating endogenous insulin secretion, particularly in type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM).
Human C peptide has shown promise in the treatment of diabetic complications. A series of clinical trials have suggested that C-peptide replacement therapy might be beneficial in patients with T1DM, improving renal function, nerve conduction, and microvascular blood flow.
Showing the single result
SALE
[1] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC10512826/
[2] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC8000702/
[3] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC4317306/
[4] https://diabetesjournals.org/care/ article/35/3/465/28711/ Persistence of Prolonged C peptide Production in
[5] https://diabetesjournals.org/care/ article/44/2/390/35493/ Clinical Impact of Residual C-Peptide Secretion in
[6] https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC9543865/
ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY.
DISCLAIMER: These products are intended solely as a research chemical only. This classification allows for their use only for research development and laboratory studies. The information available on our Direct Peptides website: https://direct-peptides.com is provided for educational purposes only. These products are not for human or animal use or consumption in any manner. Handling of these products should be limited to suitably qualified professionals. They are not to be classified as a drug, food, cosmetic, or medicinal product and must not be mislabelled or used as such.
401 N. Mills Ave, Ste B, Orlando, FL 32803, United States